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Abstract
 
Cytotoxic T lymphocytes (CTLs) play a vital part in controlling viral replication during hu-
man viral infections. Most studies in human infections have focused on CTL specificities in
chronic infection and few data exist regarding the specificity of the initial CTL response in-
duced in acute infection. In this study, HIV-1 infection in persons expressing human histo-
 
compatibility leukocyte antigen (HLA)-A
 
*
 
0201 was used as a means of addressing this issue. In
chronic infection, the dominant HLA-A
 
*
 
0201–restricted CTL response is directed towards the
epitope SLYNTVATL (“SL9”) in p17 Gag (residues 77–85). This epitope is targeted by 75%
of HLA-A
 
*
 
0201–positive adults, and the magnitude of this A
 
*
 
0201-SL9 response shows a
strong negative association with viral load in progressive infection. Despite using the highly
sensitive peptide–major histocompatibility complex tetramer and intracellular cytokine assays,
responses to the SL9 epitope were not detectable in any of 11 HLA-A
 
*
 
0201–positive subjects
 
with acute HIV-1 infection (
 
P 
 
5
 
 2 
 
3
 
 10
 
2
 
6
 
), even when assays were repeated using the SL9
peptide variant that was encoded by their autologous virus. In contrast, multiple responses
(median 3) to other epitopes were evident in 7 of the 11 A
 
*
 
0201–positive subjects. Longitudi-
nal study of two subjects confirmed that the A
 
*
 
0201-SL9 response emerged later than other
CTL responses, and after viral set point had been reached. Together, these data show that the
CTL responses that are present and that even may dominate in chronic infection may differ
substantially from those that constitute the initial antiviral CTL response. This finding is an
important consideration in vaccine design and in the evaluation of vaccine candidates.
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Introduction
 
Virus-specific CTLs play a critical role in the control of vi-
ral infections (1–9). Studies in the lymphocytic choriomen-
ingitis virus (LCMV) mouse model have most clearly
shown that the early antiviral cellular immunity that is gen-
erated strongly influences the subsequent course and out-
come from the infection (10). Similar conclusions may be
drawn from investigations of human viral infections (3–5,
11–14). This implies that the immune responses that are
observed in the chronic phase of persistent virus infections
may largely be a consequence of what has occurred ini-
tially, and that perhaps the most important antiviral im-
mune responses to understand are those responsible for
early control of viremia in acute infection. Recent studies
 
in the simian immunodeficiency virus (SIV)
 
1 
 
macaque
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model strongly support this hypothesis (15). In the design
and testing of vaccines, it is vital to know whether the CTL
specificities differ significantly between acute and chronic
infection. If differences do exist, it is necessary to determine
which responses should optimally be generated by a candi-
date vaccine.
HIV-1 infection offers an excellent system in which to
compare immune responses in acute and chronic infection.
In this infection, CTLs are centrally involved both in the
initial containment of viremia in acute infection and in
limiting viral replication in chronic infection (16–30).
However, evidence accumulating both from animal models
and human viral infections indicate that significant differ-
ences exist between the effectiveness of CTLs of different
specificities in controlling viremia (28–39). A recent study
in the SIV macaque model of AIDS virus infection showed
that initial immune pressure was directed mainly through
an epitope in Tat, whereas one in Gag did not appear to be
under strong immune selection pressure (15). Thus, from
these data, it is likely that CTLs of different specificities
may show dramatic differences in the contribution that
each may make to the successful control of viremia.
The best studied HIV-specific CTL response is the dom-
inant HLA-A
 
*
 
0201–restricted specificity that is directed to-
wards an epitope in p17 Gag, SLYNTVATL (residues 77–
85; references 22 and 40–46), referred to as “SL9”. In four
independent studies of A
 
*
 
0201-positive adults with chronic
HIV infection, 75% of persons studied had a detectable
response towards this epitope (22, 44–46). Using SL9-
A
 
*
 
0201 peptide–MHC tetrameric complexes, a strong
negative association was shown between levels of SL9-
A
 
*
 
0201 CTLs and viral load in A
 
*
 
0201-positive adults with
chronic HIV infection (22). This widely quoted landmark
study has provided strong indirect evidence that A
 
*
 
0201-
SL9–specific CTLs are effective in controlling HIV replica-
tion in chronic infection. This has led to the suggestion
that an effective vaccine should induce this response.
To determine whether A
 
*
 
0201-SL9–specific CTLs play
an important role in the initial control of viremia in acute
infection, the HIV-specific CTL responses were character-
ized in 11 subjects with A
 
*
 
0201 who were enrolled early in
the course of HIV infection, in 8 cases before seroconver-
sion. Although CTL responses were observed in the major-
ity of these subjects, none made a detectable response to
the A
 
*
 
0201-SL9 epitope.
 
Materials and Methods
 
Subjects Studied.
 
The 11 A
 
*
 
0201-positive subjects studied in
early HIV infection were recruited from persons presenting to the
Massachusetts General Hospital between 1997 and 1999 who
were diagnosed with acute HIV infection. The relevant clinical
data for these subjects are described in Table I. All but three of
the subjects were enrolled before seroconversion: three subjects
(AC14, AC23, and AC32) were enrolled within 180 d of sero-
conversion, as defined by an adapted ELISA assay for HIV Ab
(47), and one subject (AC29) was included using clinical criteria
that supported a diagnosis of HIV infection within the previous 3
 
mo. These included a known high-risk exposure to HIV infec-
tion, by history a clinical syndrome consistent with acute HIV in-
fection, and a viral load at the time of presentation of 
 
.
 
750,000
RNA copies/ml plasma that would be highly unusual as a steady-
state viral load in chronic infection (14, 48). All 11 subjects were
initially studied before initiation of highly active antiretroviral
therapy (HAART) as detailed. An additional A
 
*
 
0201-positive
subject PI004 whose date of acquiring HIV infection was less cer-
tain, and who was never treated with HAART, was also studied
as described below. The first sample available for study on PI004
was 7 wk after the first positive HIV Ab test on this subject. An
HIV Ab test 21 wk previous to this had been negative.
 
HLA Class I Tissue Typing and HLA-A2 Subtyping.
 
HLA
class I typing and A2 subtyping were performed by sequence-spe-
cific primer (SSP)-PCR (49). Only subjects with A
 
*
 
0201 were
included in the study.
 
Peptides.
 
PBMCs in each of the 11 subjects with early HIV
infection were screened for recognition in enzyme-linked immu-
nospot (Elispot) assays of epitopes within p17 Gag, p24 Gag, Nef,
RT, gp41, gp120, Tat, and Rev using overlapping peptides 12–
20 amino acids in length that overlapped by 10 amino acids.
Overall, 290 overlapping peptides were used to span these 8 pro-
teins. In addition, from a total of 130 published optimal epitope
peptides (50), those that were presented by HLA class I molecules
expressed by each subject studied (median 24 peptides) were
tested for recognition in Elispot assays. The sequences for the
peptides corresponded to the B clade SF2 sequence. Gag, Nef,
RT, and gp120 peptides were provided by the National Institute
for Biological Standards and Control Centralized Facility for
AIDS Reagents, supported by European Union Program EVA
and the UK Medical Research Council; 12 additional overlap-
ping p17 Gag peptides, gp41, Tat, and Rev peptides were syn-
thesized commercially (Research Genetics) or at the Massachu-
setts General Hospital Peptide Synthesis Core Facility.
 
Elispot Assays.
 
Fresh PBMCs were plated in 96-well polyvi-
nylidene plates (Millipore) that had been precoated with 0.5 
 
m
 
g/
ml anti–IFN-
 
g
 
 mAb, 1-DIK (Mabtech). The peptides were
added in a volume of 20 
 
m
 
l and PBMCs were added at 100,000
cells/well in a volume of 180 
 
m
 
l R10 medium (RPMI 1640
[Sigma-Aldrich], 10% FCS [Sigma-Aldrich], and 10 mM Hepes
buffer [Sigma-Aldrich] with antibiotics [2 mM 
 
l
 
-glutamine, 50
U/ml penicillin-streptomycin]). The end concentration of the
peptides was 10 
 
m
 
M. The plates were incubated overnight at
37
 
8
 
C, 5% CO
 
2
 
, and developed as described previously (51, 52).
The number of specific T cells was calculated by subtracting the
negative control values. The background was 
 
,
 
20/10
 
6
 
 PBMCs
(2 spots/well at 100,000 PBMCs/well) in all cases. Responses of
 
.
 
60 IFN-
 
g
 
 spot-forming cells/10
 
6
 
 PBMCs were therefore sig-
nificant positive responses, and these were reconfirmed in intra-
cellular IFN-
 
g
 
 staining assays (see below). Wells that contained
 
.
 
30 spots were not used for accurate quantification. Assays were
repeated using lower input numbers of cells as necessary and in
duplicate in order to quantitate responses to individual peptides
more accurately.
 
Intracellular IFN-
 
g
 
 Staining.
 
Intracellular cytokine staining
(ICS) assays were performed as described elsewhere (53–55). In
brief, 0.2–1.0 
 
3
 
 10
 
6
 
 PBMCs were incubated with 4 
 
m
 
M peptide
and 1 
 
m
 
g/ml each of the mAbs anti-CD28 and anti-CD49d
(Becton Dickinson) at 37
 
8
 
C, 5% CO
 
2
 
 for 1 h, before the addition
of 10 
 
m
 
g/ml of Brefeldin A (Sigma-Aldrich). After a further 6 h
incubation at 37
 
8
 
C, 5% CO
 
2
 
, the cells were placed at 4
 
8
 
C over-
night. PBMCs were then washed and stained with surface Abs
anti-CD8 and anti-CD3 (Becton Dickinson) at 4
 
8
 
C for 20 min. 
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PBMCs that were also stained with tetramers were incubated
with the tetramer at 4
 
8
 
C for 30 min before the addition of the
surface Abs. After washing, the PBMCs were then fixed and per-
meabilized (Caltag) and anti–IFN-
 
g
 
 mAb was added (Becton
Dickinson). Cells were then washed and analyzed. Quadrant
boundaries for IFN-
 
g
 
 staining were established by exclusion of
 
.
 
99.97% of control CD8
 
1
 
 
 
T cells.
 
Peptide–MHC Tetramer Assays.
 
Peptide–MHC tetramers
were synthesized as described previously (42, 56). The tetramer
used in these studies was the HLA-A
 
*
 
0201–SLYNTVATL com-
plex. HLA heavy chain was expressed in 
 
Escherichia coli
 
 with an
engineered COOH-terminal signal sequence containing a bio-
tinylation site for the enzyme BirA. After refolding of heavy
chain, 
 
b
 
2
 
m, and peptide, the complex was biotinylated by BirA
(Avidity) in the presence of ATP-Mg
 
2
 
1
 
 (Sigma-Aldrich). After
purification by gel filtration and anion exchange chromatography,
tetramer formation was induced by the addition of streptavidin.
Use of PE-labeled streptavidin enabled antigen-specific cells to be
visualized by flow cytometry.
Staining of lymphocytes was performed by incubating 500,000
PBMCs for 30 min at 4
 
8
 
C with the appropriate tetramer at 0.5
mg/ml of tetramer, then for a further 20 min with saturating
amounts of peridinine chlorophyll protein (PerCP)-conjugated
anti-CD8 mAb and allophycocyanin (APC)-conjugated anti-
CD4 mAb (Becton Dickinson). Stained samples were analyzed
on a FACSCalibur™ flow cytometer using CELLQuest™ soft-
ware (Becton Dickinson). Control samples for the tetramer stain-
ing were PBMCs from HLA-mismatched HIV-infected persons.
Quadrant boundaries for tetramer staining were established by
exclusion of 
 
.
 
99.97% of control CD8
 
1
 
 T cells.
 
Generation of CTL Clones, Precursor Frequency Assays.
 
CTL
clones were generated using methods described previously (57).
 
In brief, PBMCs were plated out in 96-well plates at limiting di-
lution (30 cells/well down to 1 cell/well) and cultured with irra-
diated allogeneic feeder PBMCs at 50,000 cells/well in a final
volume per well of 200 
 
m
 
l of R10. The anti-CD3 mAb, 12F6,
was added at 10 
 
m
 
g/ml. On day 5 and once weekly thereafter,
the medium was changed with R10 medium containing 50
U/ml of rIL-2 (provided by Dr. M. Gately, Hoffmann-
La Roche, Nutley, NJ). Wells were screened for specific recog-
nition of HLA-matched, peptide-pulsed, 
 
51
 
Cr (New England
Nuclear)-labeled EBV-transformed B lymphoblastoid cell line
(BCL) target cells after 21–28 d in culture. Wells showing high
specific recognition of the relevant peptide were then transferred
to 24-well plates and restimulated as above, except 10
 
6
 
 feeders
were added to each well and rIL-2 was added on day 0. Expanded
wells were then retested for lytic activity from 14 d of culture on-
wards, and maintained in culture by monthly restimulations as
described (57).
 
Cr Release Assays.
 
BCL target cells were labeled with 
 
51
 
Cr by
incubation of pelleted BCL with 50 
 
m
 
Ci of Na
 
2
 
CrO
 
4
 
 (New En-
gland Nuclear) for 1 h at 37
 
8
 
C, 5% CO
 
2. Targets were washed
three times and then incubated with peptide dilutions in the pep-
tide titration assays for a further 90 min, before addition of effec-
tors. The supernatants were harvested after a further 4–6 h of in-
cubation at 378C, 5% CO2 (58).
Sequencing of Viral DNA and Sequence Analyses. Genomic
DNA was extracted from frozen PBMC pellets (3 3 106 cells) us-
ing the Puregene™ DNA isolation kit (Gentra). HIV Gag se-
quences were amplified by nested PCR using inner and outer
primer sets and PCR conditions as described previously (44). For
sequencing cloned viral sequences, 2 ml of the gel-purified PCR
product was used for ligation of the Gag sequences into the
Topo2 cloning plasmid according to the manufacturer’s recom-
Table I. Subjects with Early/Acute HIV Infection Studied
Patient
ID Age Sex Race
HIV1/2
ELISA
Western
blot
Mode of
exposure Viral load
CD41
cell count Therapy
y
Copies/ml
at diagnosis Cells/mm3
AC01 31 M Caucasian Negative ND Sexual 0.25 3 106 1,023 ZDV, 3TC, IDV
AC07 22 F Caucasian Negative ND Sexual 10.6 3 106 131 D4T, 3TC, NFV
AC03 30 M Caucasian Negative ND Sexual .0.75 3 106 463 ZDV, 3TC, NFV
AC04 35 M Caucasian Negative ND Sexual 9.62 3 106 N/A ZDV, 3TC, NFV
AC32 34 M Caucasian Positive IND Sexual 0.2 3 106 554 D4T, 3TC, EFV
AC13 32 M Caucasian Negative ND Sexual 0.73 3 106 667 ZDV, 3TC, IDV
AC22 29 M Caucasian Negative ND Sexual 95.5 3 106 281 D4T, DDI, HU, NFV
AC26 45 M Caucasian Positive IND (3 band) Sexual 2.15 3 106 390 ZDV, 3TC, IDV
AC23 36 M Caucasian Positive Positive* Sexual 0.12 3 106 396 ZDV, 3TC, EFZ
AC14 46 M Caucasian Positive Positive* Sexual 0.095 3 106 981 D4T, 3TC, IND 
AC29 54 M Caucasian Positive Positive‡ Occupational .0.75 3 106 785 ZDV, 3TC, EFV
PI004 M Positive Positive 50 432 No treatment
ID, identification; ND, not done; IND, indeterminate; ZDV, zidovudine; 3TC, lamivudine; IDV, indinivir; d4T, stavudine; NFV, nelfinavir; ddI,
didanosine; HU, hydroxyurea; EFV, efavirenz.
*Diagnosed and treated within 129 d of HIV-1 infection, detuned-ELISA negative.
‡Diagnosed and treated within 129 d of HIV-1 infection, detuned-ELISA pending.184 CTL Specificities Differ in Acute and Chronic HIV Infection
mendation (Invitrogen) and plasmid DNA was obtained after
transfection of E. coli cells and DNA purification using the
QIAGEN Turbo DNA purification kit. Inserted Gag sequences
were determined from both directions on an ABI 377 sequencer
using primer sequences located in the plasmid sequence on both
sides of the insert (Topo2 cloning kit; Invitrogen). Sequence
analysis was performed using the sequencer software version
3.1.1. BLAST was used to compare sequences from each of the
study subjects with each other and sequences in the viral subsec-
tion of GenBank to screen for potential cross contamination. Sig-
nature analysis was done to verify viral sequence identity and
phylogenetic tree analyses using the Neighbor TreeMaker pro-
gram, available at the Los Alamos HIV Database web site (http://
hiv-web.lanl.gov/CONTAM/TreeMaker/TreeMaker.html), re-
vealed unique signature sequences for the individuals. These se-
quence data are available from Genbank/EMBL/DDBJ under ac-
cession nos. AF281678 and AF281801.
Results
Recognition of the HLA-A*0201–restricted p17 Gag Epitope
in Acute Infection. To characterize the HIV-specific CTL
response in acute infection for each subject enrolled, IFN-g
responses to epitopes within p17 Gag, p24 Gag, Nef,
RT, gp41, gp120, Tat, and Rev were screened in Elispot
assays using panels of overlapping 15–20-mer peptides that
overlapped by 10 amino acids to span each protein. The
approach that was used is illustrated for one subject in Fig.
1 A. In addition, individual peptides previously defined as
optimal epitopes corresponding to the HLA class I alleles
expressed by each subject were tested for recognition.
Thus, for each of the 11 A*0201-positive subjects studied
with early HIV infection, 290 overlapping 15–20-mer pep-
tides and between 11 and 29 (median of 24) optimal
epitope peptides were used to characterize the CTL re-
sponse. Overall, 78 different optimal epitope peptides were
used in the studies of 11 A*0201-positive subjects with
early infection.
None of the 11 subjects studied in this way had detect-
able CTL activity towards the A*0201-SL9 epitope (Fig. 1
B), even when responses were evaluated at several time
points in the first 12 mo after presentation. In comparison,
responses towards multiple epitopes other than SL9 (range
1–7, median 3) were observed in 7 of these A*0201-posi-
tive 11 subjects during this first year after the presumed
time of infection (59). These data clearly contrast with the
Figure 1. (A) Characterization of the HIV-specific CTL responses made in acute HIV infection. The method used is illustrated for subject AC01.
Overlapping peptides spanning p17 Gag, p24 Gag, Nef, RT, gp120, gp41, Rev, and Tat were used in Elispot assays, as well as published optimal peptides
presented by HLA-A*0201, A3, B35, or Cw4. Examples of positive and negative responses are shown. No responses to Tat or Rev overlapping peptides
were observed in this subject (not shown). SFC, spot-forming cell. (B) Proportion of A*0201-positive subjects in acute infection showing a detectable re-
sponse to the A*0201-SLYNTVATL epitope. (C) Proportion of A*0201-positive subjects in chronic infection showing a detectable response to the
A*0201-SLYNTVATL epitope, using data from four published studies. Criteria for inclusion of a published study were: demonstration of specificity of
A*0201-SL9 response by cytotoxicity assays or peptide–MHC tetramers, and more than 1 subject studied.185 Goulder et al.
frequent detection of A*0201-SL9–specific responses (in
75% of A*0201-positive adults with chronic infection; n 5
72) that has been described in four independent studies (22,
44–46) (x2 5 20.9, P 5 2 3 1026). Even restricting the
comparison to the seven A*0201-positive subjects who had
no detectable SL9 response but who showed evidence of
other HIV-specific CTL activity, the absence of an
A*0201-SL9 response remains strongly significant (P , 2 3
1024, Fisher’s exact test).
The Elispot assay has a high sensitivity but this does not
quite reach the sensitivity of the flow cytometric assays to
detect antigen-specific CD81 T cells either by intracellular
IFN-g staining after peptide stimulation, or by peptide–
MHC class I tetrameric complexes (53, 60). In addition,
tetramer assays have revealed the presence of phenotypi-
cally silent antigen-specific T cells in both murine and hu-
man viral infections (3, 38, 39). These assays were therefore
used to determine whether any low-frequency or pheno-
typically silent A*0201-SL9–specific CD81 T cells could be
detected using these highly sensitive assays. All A*0201-
positive subjects either showed responses to an A*0201–
EBV peptide, GLCTLVAML (61) and/or an A*0201
CMV peptide, NLVPMVATV (62), and/or a positive con-
trol HIV peptide in the ICS assay, but none recognized the
A*0201-SL9 epitope (Fig. 2, and data not shown). The
A*0201-SL9 tetramer and the SL9 peptide in the ICS assay
demonstrated responses to this epitope in an A*0201-posi-
tive subject 9354 with chronic infection. Thus, no pheno-
typically silent A*0201-SL9 tetramer-binding cells were
detectable in the subjects studied.
To reconfirm that no low-frequency A*0201-SL9–spe-
cific CTLs were detectable by any of the most sensitive as-
says, in two subjects a further method involving stimulation
of PBMCs with SL9 peptide before culture in IL-7–con-
taining medium (63) that has been successfully used to
detect low-frequency CTL responses (64) was employed.
However, this method was only successful in generated
SL9-specific responses in A*0201-positive subjects with
chronic infection, and not in those with acute infection
(data not shown).
Variant Epitope Sequence Encoded by Transmitted Virus Does
Not Explain the Absence of an SL9-specific CTL Response in
Acute Infection. To investigate why no responses were
generated towards the A*0201-SL9 epitope in acutely in-
fected subjects with A*0201, autologous virus was se-
quenced to determine whether mutated epitope sequences
had been transmitted. It was hypothesized that this could
explain the absence of an SL9-specific response if the autol-
Figure 2. Recognition of
SLYNTVATL only in A*0201-
positive subjects in chronic in-
fection. Intracellular staining us-
ing SL9 and a positive control
HIV peptide epitope and
A*0201-SL9 tetramer staining of
PBMCs from chronically in-
fected subject 9354 (HLA-
A*0201/3 B7/35 Cw4/7) and 2
of the 11 A*0201-positive sub-
jects studied in acute infection
(expressed as percentage of
CD81 T cells). Controls: per-
centage of CD81 T cells show-
ing intracellular IFN-g staining
after incubation with no peptide
was, respectively, 0.00% (subject
9354), 0.03% (AC29), and 0.02%
(AC13; data not shown). The
HIV peptides used as positive
controls had previously been es-
tablished as recognized by these
subjects: B7 Gag TL9,
TPQDLNTML (p24 Gag); B8
Nef FL8, FLKEKGGL; and
B14-gp41-EL9, ERYLKDQQL
(reference 50).186 CTL Specificities Differ in Acute and Chronic HIV Infection
ogous SL9-epitope sequence differed significantly from the
consensus B clade sequence. In 10 of the 11 A*0201-posi-
tive subjects enrolled, the autologous gag sequences encod-
ing the p17 Gag SL9 epitope were determined (Table II).
Only sequences encoding full-length p17 and p24 Gag
were included in the analysis. In all subjects, the predomi-
nant autologous sequence encoded either the B clade con-
sensus sequence SLYNTVATL or variants that occur very
frequently in Los Alamos database sequences (50). Even
when these A*0201-positive acutely infected subjects were
tested for recognition of autologous SL9 variants, still none
recognized his autologous epitope. (Fig. 3, A and B).
To demonstrate further that variants of SL9 should be
able to induce CTL responses, CTL clones specific for this
response were generated in chronically infected subjects
with A*0201 and the SL9 variants occurring most fre-
quently in published sequences were tested for recognition.
The five SL9 variants that were tested, together with the
clade B consensus sequence SLYNTVATL, account for
89% of the 272 B clade Los Alamos database sequences
originating in the USA (50). Many distinct patterns of vari-
ant recognition were observed, in several cases showing
that SL9 variants can be recognized as well or better than
the consensus sequence (Fig. 3, C–H). Although a formal
comparison of the ability of SL9 and the different SL9 vari-
ants to induce CTL responses was not undertaken, these
data together imply that transmission of virus that encodes
the commonly occurring SL9 variants (illustrated in Fig. 3)
is not a barrier to the generation of CTL responses towards
this epitope.
It should be noted that although the SL9 (SLYNT-
VATL) sequence is considered the consensus clade B se-
quence, as many sequences in the database contain SL9
variants as contain the consensus sequence within this
highly variable region. Thus, it is highly unlikely that the
72 A*0201 subjects studied in chronic infection were all in-
fected with virus encoding the SL9 consensus sequence.
Indeed, in one of these studies (45), only 3/11 A*0201-
negative chronically infected control subjects had virus en-
coding this consensus SL9 sequence, a virtually identical
proportion to that observed in the acutely infected
A*0201-positive subjects described here. However, even if
we restrict our analysis to the subjects with A*0201 whose
autologous virus encoded the so-called consensus SL9
epitope, the absence of an SL9 response in acute infection
still differs significantly from the chronically infected
A*0201-positive subjects, 75% of whom made a response
to SL9 (P , 0.02, Fisher’s exact test).
Late Emergence of the A2-SL9–specific CTL Response. As
the A*0201 Gag (SL9) response is clearly the dominant
A*0201-restricted HIV-specific CTL response in chronic
infection, but is rarely detectable in acute infection, acutely
infected subjects with A*0201 were followed longitudinally
in order to characterize further the timing of the develop-
ment of this response. In subject AC13, in whom five sep-
arate HIV-specific CTL specificities were targeted from the
first preseroconversion time point onwards, this response
first became detectable 20 mo after presentation (Fig. 4 A).
The presence of this response was confirmed by the ap-
pearance of staining with the A*0201 tetramer for the first
Table II. SLYNTVATL Epitope Variants Encoded in 10 of the 11 Subjects with Early/Acute HIV Infection
Deduced SLYNTVATL variant sequences
Subject Date* Clones analyzed
77
S
78
L
79
Y
80
N
81
T
82
V
83
A
84
T
85
L
AC23 11/10/89 8/8 22F 222222
AC29 03/09/99 11/11 222222222
AC04 10/17/97 13/13 22F 222222
AC01 01/31/97 11/12 22222 I 2 V 2
1/12 2222PI2 V 2
AC03 09/01/97 13/15 222222222
1/15 22222 I 222
1/15 2222222A 2
AC14 07/27/99 13/13 22222 I 2 V 2
AC13 06/25/98 11/11 222222222
AC22 10/30/99 12/14 2222222V 2
2/14 222222TV2
AC26 01/21/99 14/14 22F 222222
AC32 05/26/99 6/6 22222 I 2 V 2
*Viral sequence obtained from samples taken prior to seroconversion from all subjects except AC14, AC23, AC29, and AC32.187 Goulder et al.
time at 20 mo as well. The frequency of A*0201-SL9–spe-
cific CTLs by tetramer assay was 0.07% of PBMCs, com-
pared with 0.03% of PBMCs in the Elispot assay (data not
shown). The magnitude of this response increased once it
had developed, and in the absence of any substantial reduc-
tion in the magnitude of the other five responses.
Although the pattern of responses in subject AC13 over
time is of interest, these data are complicated by the fact
that AC13 had previously received HAART from 2 wk af-
ter presentation and had also undergone two treatment
interruptions. At the time the A*0201 Gag response
emerged, AC13 was not on antiretroviral therapy and had
detectable viremia. In an additional A*0201-positive sub-
ject PI004, recruited from a separate small cohort of acutely
infected persons from Montreal, who was untreated
throughout the time of study, a similar phenomenon of the
late appearance of SL9-specific CTLs in the HIV-specific
response was observed. This response was detectable 5 mo
later than three responses that were present from the first
time point available for study onwards (Fig. 4 B). Of note,
in both AC13 and PI004, initial control of viremia in acute
infection had been achieved in the absence of an A*0201-
SL9–specific response. In AC13, the viral load had fallen
from 730,000 to 5,000 HIV-1 RNA copies/ml plasma be-
fore the initiation of HAART. In PI004, the viral load for
the first four time points shown, before the appearance of
Figure 3. (A and B) Recognition of SLYNTVATL and
autologous SL9 variant in Elispot assays. (A) Positive con-
trol chronic subject 161j, recognition of SL9, and autolo-
gous variant SLFNTVATL (reference 45). (B) Acute sub-
ject AC04: no recognition either of SL9 or autologous SL9
variant. Data from the other 10 A*0201 subjects in acute
infection are not shown. SFC, spot-forming cell. (C–H)
Recognition of SL9 and SL9 variants that arise most often
in HIV infection (.90% of published B clade United
States originating sequences; reference 50) using CTL
clones derived from PBMCs from chronically infected
A*0201-positive subjects.188 CTL Specificities Differ in Acute and Chronic HIV Infection
the A2-Gag–specific CTL response, was between 50 and
400 RNA copies/ml plasma. Thus, the A*0201-SL9–spe-
cific response is not required for the initial control of vire-
mia in A*0201-positive subjects.
Discussion
These studies show that the HIV-specific CTL epitopes
that may dominate in chronic infection may play no part in
the critical antiviral CTL response associated with initial
clearance of virus in acute infection. Not one of 11
A*0201-positive subjects with early HIV infection had de-
tectable CTL responses towards the p17 Gag SL9 epitope
that is recognized in 75% of A*0201-positive adults with
chronic infection (P 5 2 3 1026; references 22 and 44–
46). This absence of a response to SL9 in acute infection
was especially striking in the seven A*0201 subjects who
showed readily detectable responses to multiple other HIV-
specific epitopes (P , 0.0002). Finally, the delayed appear-
ance of an A2-restricted CTL response towards the SL9
epitope well after responses were detectable to other
epitopes was confirmed in longitudinal studies of two sub-
jects.
In addition to the consensus SL9 sequence, autologous
variants were also tested, and there was also no recognition
of either autologous or consensus SL9 sequence. This was
important because previous studies in EBV have suggested
viral evolution over time to mutate immunodominant
epitopes (65). We have shown previously that mutations
within and adjacent to the SL9 epitope do not alter pro-
cessing to affect recognition of the SL9 variant epitope
(66). Thus, there is no clear explanation from the viral se-
quence data presented for the absence of the A*0201-SL9
response in acute infection.
To determine whether A*0201-SL9–specific CTLs were
present in early infection that were functionally inert (3,
38, 39), tetramer assays showed conclusively that no phe-
notypically silent antigen-specific CD81 T cells could be
detectable in the A*0201 subjects studied in early HIV in-
fection. In longitudinal studies of subject AC13, A*0201-
Figure 4. (A and B) Longitudinal study
of HIV-specific epitope recognition in sub-
ject AC13 (presenting preseroconversion)
and subject PI004 (presenting 7–28 wk after
seroconversion). Before the onset of
HAART in subject 5192d, the viral load
had declined from 730,000 HIV-1 RNA
copies/ml plasma to 5,000 copies/ml
plasma. Subject PI004 did not receive anti-
retroviral therapy at any time. Peptides that
were recognized (references 50 and 76):
A2-p17 Gag SL9, SLYNTVATL; A2-gp41
SV10, SLLNATAIAV; B14-p24 Gag DA9,
DRFYKTLRA; A2 Vpr, AIIRILQQL;
Cw5-Rev SL9 SAEPVPLQL, B14-gp41
ERYLKDQQL; B57-Gag TW10,
TSTLQEQIGW; B57-Gag IW9, ISPRTL-
NAW; B57-Gag KF11, KAFSPEVIPMF;
B57-Gag QW9, QASQEVKNW; B8-p24
Gag EI8, EIYKRWII; and B8 Nef FL8,
FLKEKGGL. SFC, spot-forming cell.189 Goulder et al.
SL9 tetramer-binding cells were detectable only when
SL9-specific responses in the Elispot and intracellular cy-
tokine assays became evident.
These data are critical in relation to vaccine design, as
they raise the question of whether the responses that domi-
nate in chronic infection are in fact important in control of
HIV, as was believed previously (22). It is clear from sub-
jects AC13 and PI004 that initial control of viremia in
these two subjects was achieved without any contribution
from the A*0201-SL9 response. Thus, an A*0201-SL9 re-
sponse is evidently not required for effective control of
acute viremia. It is possible that the A*0201-SL9 CTL re-
sponse in chronic infection may only be associated with
control of viremia indirectly, through the action of CTLs
of different HIV specificities, or via HIV-specific T helper
responses. Resolving this important question will require
further detailed work to understand the HIV-specific T re-
sponse in A*0201-positive subjects in its entirety, as op-
posed to the response to a single epitope in chronic infec-
tion. Greater focus needs to be placed additionally on
characterizing the CTL specificities that make up the acute
response in HIV infection.
These data are of importance also to the interpretation of
vaccine trials that aim to generate CTL responses. Recent
analysis of HIV-uninfected persons immunized with a ca-
narypox vector–based vaccine revealed no responses that
were detectable in vaccinees towards the A*0201-SL9
epitope using tetramers. However, responses towards other
epitopes in Gag were detectable using overlapping peptides
spanning Gag in Elispot assays (67). These initially some-
what puzzling data would be consistent with this study.
Thus, demonstration of the late appearance of the A*0201-
SL9 response in natural HIV infection indicate that the en-
tire HIV-specific CTL response cannot be estimated ade-
quately by focusing on this single specificity.
It remains unresolved why the A*0201-SL9 responses
arise late. The factors likely to contribute towards immuno-
dominance in CTL responses (68) in this case include the
binding affinity of SL9 to HLA-A*0201 (69, 70), the effi-
ciency of processing of the SL9 epitope (41, 66, 71), and
the presence of CTL escape (44, 72) in responses that were
previously immunodominant.
It is clear from binding studies already performed that
SLYNTVATL is not a strong binder to A*0201 (45, 73–
76), although all the SL9 variants tested do indeed bind.
The gp41–A*0201 epitope, SLLNATAIAV (SV10), that
dominates the early CTL response in subject AC13 (Fig. 4
A) in fact in recent studies proved to be the strongest
binder to A*0201 of all HIV-1 peptides tested that had
been selected on the basis of motif (76). Thus, the relatively
weak binding of SL9 to A*0201 may contribute to the rel-
atively poor immunogenicity of this epitope.
A second factor likely to contribute to the dominance of
the early CTL response would be the efficiency with
which individual epitopes are processed. It might be antici-
pated that epitopes derived from the regulatory and acces-
sory proteins such as Tat, Rev, and Nef, expressed in abun-
dance on the surface of infected cells early in the viral life
cycle (77), might dominate the acute antiviral CTL re-
sponse (15). However, in the cohort of 19 subjects with
acute HIV infection being studied in Boston, Gag-specific
epitopes were in fact targeted more frequently than Nef-
specific at preseroconversion time points (33 vs. 19%; refer-
ence 59). Furthermore, no Nef-, Tat-, or Rev-specific
A*0201-restricted responses were detectable in any of the
11 A*0201 subjects studied here in early HIV-1 infection
(data not shown). Thus, low expression of Gag (relative to
Tat, Rev, or Nef) in acute infection does not appear to be
an explanation for the absence of A*0201-SL9 responses at
this time.
A further possible explanation for the late appearance of
the A*0201-SL9 response in the course of HIV-1 infection
would be that CTL escape occurring in the dominant
epitopes would enable previously subdominant epitopes to
become immunodominant over time (72). The limited
data available from subject PI004 (Fig. 4 B) do appear to
indicate that a substantial reduction in the dominant
HLA-B57–restricted responses towards p24 Gag epitope
TSTLQEQIGW (34, 50) has occurred immediately before
appearance of the A*0201-SL9 and several other responses
that previously were undetectable. In AC13, the data are
more difficult to interpret, as this subject was twice treated
with HAART, but the appearance is more suggestive in
this case that the A*0201-SL9 response emerges at a time
when the CTL response as a whole is increasing in magni-
tude. These and other subjects who show the late appear-
ance of particular epitopes clearly warrant further study in
this regard.
It is important to note that, although SL9 is the domi-
nant A*0201-restricted response in chronic infection, it is
not commonly the dominant HIV-specific CTL response
overall (34, 78–80). Thus, it is not unexpected to see that
SL9 is subdominant to B14- and B57-restricted responses
in subjects AC13 and PI004, and that the SL9 response
does not increase to become dominant to these other re-
sponses.
The closest precedent for this phenomenon may be in
human EBV infection, in which lytic as opposed to latent
antigen-specific responses dominate in acute infection (2,
81). However, this difference corresponds to the different
biological phases of EBV infection. In HIV infection, there
is no indication that Gag is not expressed in acute infection;
in fact, in 5/7 HLA-A3–positive subjects studied at prese-
roconversion, p17 Gag-specific HLA-A3–restricted activity
was a major component part of the initial anti-HIV im-
mune response (59). There are indications, both in studies
of SIV (15) and HIV (59, 82), and also in hepatitis C virus
infection (3, 83), that many clear-cut differences in the
specificities of the CTL response in acute and chronic viral
infections may exist. However, these data presented with
respect to the A*0201-SL9 specificity are apparently the
first unequivocal demonstration of this phenomenon.
In conclusion, these data show that the HIV-specific
CTL responses that are present in acute infection may differ
substantially from those that are frequently detectable in
chronic infection. The best-studied response in chronic190 CTL Specificities Differ in Acute and Chronic HIV Infection
HIV infection is seen to play little or no part in the antiviral
immune response in acute infection that is so critical in de-
termining the ultimate outcome from infection. Further
studies are needed to assess the importance of the CTL re-
sponses that are frequently detectable in subjects with
chronic infection, to determine whether these, or the re-
sponses present in acute infection, or both, are effective re-
sponses that should be incorporated into HIV vaccine de-
sign.
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